No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
SIBN Si-Bone
- 14.050
- +0.580+4.31%
Close May 31 16:00 ET
- 14.070
- +0.020+0.14%
Post 19:06 ET
578.93MMarket Cap-13009P/E (TTM)
14.100High13.440Low425.11KVolume13.490Open13.470Pre Close5.94MTurnover1.15%Turnover RatioLossP/E (Static)41.20MShares29.51052wk High3.50P/B520.82MFloat Cap13.34052wk Low--Dividend TTM37.07MShs Float37.210Historical High--Div YieldTTM4.90%Amplitude7.200Historical Low13.964Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Osteotec Announces Exclusive UK and Ireland Distribution Agreement With SI-BONE
NEWBURY, England, May 16, 2024 /PRNewswire/ -- Osteotec, the market-leading manufacturer and distributor of medical devices, is pleased to announce a new partnership with SI-BONE to exclusively distr
Osteotec Announces Lisa Watts as National Sales Manager of New Spine Division
NEWBURY, England, May 15, 2024 /PRNewswire/ -- Osteotec, the market-leading manufacturer and distributor of medical devices, today announced it has strengthened its leadership team with the appointme
SI-BONE, Inc.'s (NASDAQ:SIBN) Price In Tune With Revenues
With a price-to-sales (or "P/S") ratio of 4.5x SI-BONE, Inc. (NASDAQ:SIBN) may be sending bearish signals at the moment, given that almost half of all Medical Equipment companies in the United States
Si-Bone Launches IFuse Bedrock Granite Implant System
Si-Bone | 10-Q: Quarterly report
SI-BONE Is Maintained at Overweight by Morgan Stanley
SI-BONE Is Maintained at Overweight by Morgan Stanley
Comments
The recent insider sale of SI-BONE shares and the absence of insider purchases over the past year might worry investors. The low level of insider ownership and recent selling activity could indicate a misalignment between insiders and other shareholders.
Have Insiders Sold SI-BONE Shares Recently?SI-BONE's high P/S ratio is justified by its superior revenue growth and future prospects. Shareholders are confident in the company's future revenues, keeping the share price buoyant.
Multiple insider stock sales over the past year, including a notable sale at the current price, suggests reduced confidence in the firm's equity. The lack of insider purchases enhances these doubts about prospective share performance. Even with insider ownership, the ongoing sell-off hints at a careful approach to buying the company's stock.
The company's future could potentially bright despite underperformance, due to revenue growth. However, past unprofitability may have affected investors' sentiment. Note the 3 warning signs for SI-BONE as possible risks.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg